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We have analysed the occurrence of the extracellular glycoprotein vitronectin in carcinomas and normal tissue of human breast.
Immunohistochemical analysis of carcinomas revealed a strong vitronectin accumulation in extracellular matrix (ECM) around some cancer
cell clusters and in the subendothelial area of some blood vessels. In normal tissue, vitronectin had a homogeneous periductal occurrence,
with local accumulation much lower than that in the carcinomas. Using a new solid phase radioligand assay, the vitronectin concentrations of
extracts of carcinomas and normal breast tissue were determined and found to be indistinguishable. Comparison of the vitronectin and the
hemoglobin concentrations of the extracts showed that their vitronectin content was not derived from blood contamination. Vitronectin
mRNA was undetectable in both carcinomas and normal tissue. We conclude that vitronectin is not synthesised locally in breast tissue but
derived by leakage from vessels, followed by extracellular accumulation in patterns distinctly different in carcinomas and normal tissue. The
observation of a high vitronectin content in the carcinomas and its localisation in the tissue contributes to the clarification of the role of
vitronectin in tumour biology in interaction with the plasminogen activation system and integrins.D 2003 Elsevier Science B.V. All rights reserved.Keywords: Breast; Carcinoma; CD34; PAI-1; Vitronectin1. Introduction
Vitronectin is an Mr 75,000 extracellular glycoprotein
with 459 amino acids, synthesised mainly by liver cells. It
occurs in blood plasma in a concentration of about 4 AM,
but is also deposited extravascularly in many tissues (for
reviews, see Refs. [1–3]). The three-dimensional structure
of vitronectin is unknown, but it is known to be composed
of several independently folded domains. As mentioned
from the N terminus, these include the 44-residue-long
somatomedin B domain, a connecting region, and two
hemopexin-like domains. Vitronectin can undergo multi-
merisation in a poorly defined manner, which is believed to
be partially dependent on intramolecular disulfide bridges
(for reviews, see Refs. [2,3]). The connecting region of
vitronectin contains an Arg-Gly-Asp (RGD) sequence, con-0925-4439/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
doi:10.1016/S0925-4439(03)00059-0
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activator
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avh3, avh5, and aIIbh3 (for a review, see Ref. [1]). The
somatomedin B domain binds to plasminogen activator
inhibitor-1 (PAI-1) and urokinase-type plasminogen activa-
tor receptor (uPAR) (for reviews, see Refs. [4–7]). Binding
of PAI-1 competes with the binding of uPAR and integrins,
enabling PAI-1 to regulate cell adhesion and migration [8–
11]. Vitronectin has also been reported to bind to elastin
[12], sulfated glycosaminoglycans [13], fibrin [14], and
several collagens [15]. Vitronectin interacts with compo-
nents of the complement system (for reviews, see Refs.
[3,13]). Recently, the availability of mice with targeted
vitronectin gene disruption has made it possible to test
rigorously the functions of vitronectin. Such mice develop
to term, grow to adulthood, and are fertile [16]. They do,
however, exhibit certain phenotypic abnormalities, report-
edly including increased wound fibrinolysis and decreased
microvascular angiogenesis [17] and abnormalities in
thrombus formation [18–20].
The binding of PAI-1 and uPAR to vitronectin suggests a
functional interaction between vitronectin and the plasmi-
nogen activation system. The plasminogen activation sys-ed.
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stasis of malignant tumours, the basic idea being that
urokinase-type plasminogen activator (uPA) released in tu-
mours catalyses the proteolytic conversion of the inactive
zymogen plasminogen to the active proteinase plasmin,
which in turn catalyses degradation of basement membranes
and extracellular matrix (ECM), and thus facilitates cancer
cell invasion into the surrounding tissue (for a review, see
Ref. [21]). The system is also involved in other processes in
tumours which may collectively be called cancer cell-di-
rected tissue remodelling, like desmoplasia and angiogene-
sis, and PAI-1 and uPAR are as important as uPA for the
functions of the system. The proposed role of the system has
been strongly supported by observations with transplanted
and chemically and virally induced tumours on mice with
targeted disruptions of the genes for the components of the
system (for reviews, see Refs. [5,6]). The uPA and PAI-1
levels in tumours are informative prognostic markers
[22,23].
To evaluate the possible functions of vitronectin in
tumours, which have been suggested mainly from cell
culture model systems, we have studied vitronectin local-
isation in human breast carcinomas and normal human
breast tissue by immunohistochemistry. We have developed
a solid phase radioligand assay for vitronectin, utilising the
high affinity binding between vitronectin and PAI-1, and
used it for measuring vitronectin levels in extracts of human
breast carcinomas and normal breast tissue. We have also
evaluated the occurrence of vitronectin mRNA in breast
tissue by RT-PCR.2. Materials and methods
2.1. Tissues, cells, and body fluids
For biochemical analysis, samples from invasive breast
carcinomas and from normal breast tissue were frozen in
liquid nitrogen and stored at  80 jC until use. The 70
tumour samples analysed included a mixture of ductal and
non-ductal (tubular, lobular, and medullary) invasive carci-
nomas, one ductal carcinoma in situ, and six lymph node
metastases. The 19 normal breast tissue samples were from
surgical reductions of breast hypertrophia. While still fro-
zen, the tissue samples were homogenized in 0.1 M Tris, pH
8.1, 0.5% Triton X-100, 10 mM EDTA, and 10 Ag/ml
Trasylol (10 Al/mg wet weight of tissue) with an Ultraturrax
with a S 25 N8G head (24,000 rpm) at 4 jC and centrifuged
at 10,000 g for 10 min in order to remove cell debris and
nuclei [24]. The supernatants were analysed. The total
protein concentration was determined by the Bradford
method, using bovine serum albumin (BSA) as a standard.
For immunohistochemistry, samples from six primary,
invasive ductal breast carcinomas and 10 samples from
normal breast tissue were either frozen in liquid nitrogen
or formalin-fixed and paraffin-embedded. Four-micrometersections were prepared from frozen as well as from for-
malin-fixed, paraffin-embedded tissue, and mounted on
silanised glass.
The human hepatoma cell line HepG2 (ATCC HB 8065)
was cultured at standard conditions, in Dulbecco’s modified
Eagle’s medium with 10% fetal bovine serum.
Human blood plasma was prepared from 11 healthy
volunteers by standard methods. Red blood cells were
prepared from blood by a standard method and extracted
with the same method as described above for extracting
tissue samples.
2.2. Vitronectin
Multimeric vitronectin was purchased from BD Bio-
sciences (Franklin Lakes, NJ, USA). Its multimeric state
was controlled by FPLC gel filtration on a Superdex 200
HR10/30 column (Pharmacia, Sweden). The multimeric
vitronectin to be used for standard curves was kept in
aliquots at  80 jC. It was thawed at the same day as the
assay and never refrozen.
2.3. PAI-1
To be able to label PAI-1 radioactively, the nucleotide
sequence coding for the phosphorylation target amino acid
sequence for heart muscle kinase (HMK), ARRASV, was
fused to the N terminus of the coding sequence for wild-type
PAI-1 [25]. The corresponding protein was expressed in E.
coli. For the construction of the HMK-PAI-1 expression
plasmid, an oligonucleotide corresponding to the HMK
target sequence and a cDNA corresponding to the coding
sequence for PAI-1, excised from the plasmid pUC-PAIcas
[26], were inserted into the pET-HTG vector [27] by stand-
ard methods, creating the expression vector pET-PAI. E. coli
strain BL21(DE3) pLysS cells were then transformed with
this construct by electroporation. For expression and puri-
fication of HMK-PAI-1, the transformed bacteria were
grown in a large-scale culture at 30 jC for 16 h, followed
by incubation in the presence of 0.5 mM isopropyl-h-D-
thiogalactopyranoside at 37 jC for 2 h. The following
procedures were then performed at 0–4 jC. The bacteria
were pelleted by centrifugation, resuspended in 20 mM
sodium acetate, pH 5.6, 100 mM NaCl, using 3-ml buffer
per gram of bacteria, and lysed with a French Press. The
crude lysate was centrifuged at 30,000 g for 30 min and
filtered through a 0.8-Am filter. The crude lysate was applied
to a 50-ml CM-Sephadex C-50 column (Pharmacia), equi-
librated with 20 mM sodium acetate, pH 5.6, 100 mM NaCl.
The column was washed with 250–500-ml equilibration
buffer. The bound protein was eluted with 20 mM sodium
acetate, pH 5.6, 1 M NaCl. The pH was adjusted to pH 8.1.
A second purification step consisted in immunoaffinity
chromatography on a monoclonal anti-PAI-1 antibody
[28]. The eluted protein was dialysed against 10 mM
HEPES, pH 6.5, 1 M NaCl. The prepared HMK-PAI-1
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polyacrylamide gels, and had the N-terminal sequence
ARRASVGSHVH. . ., as expected after proteolytic cleavage
of the original N-terminal M-residue.
To label HMK-PAI-1 with 32P, 10 Ag of purified active
HMK-PAI-1 was mixed with 37.5 units HMK (Sigma-
Aldrich, St. Louis, MO, USA) and 0.5 mCi [g32P]ATP
(7000 Ci/mmol; Amersham, UK) in a total volume of 37.5-
Al 10 mM HEPES, pH 6.5, 200 mM NaCl, 120 mM
MgCl2, 0.2% bovine serum albumin (BSA). The sample
was incubated at 37 jC for 1 h. After the incubation,
radiolabeled protein and unreacted [g32P]ATP were sepa-
rated by gel filtration on a PD-10 column (Pharmacia) in 50
mM Tris, pH 7.4, 0.14 M NaCl, 1% BSA, 10 mM EDTA,
0.01% Tween-20. All fractions containing 32P-PAI-1 were
pooled. The resulting concentration of 32P-PAI-1 was
normally around 200 nM. The activity of the labelled
PAI-1 preparation was around 7000 Ci/mmol. The prepared
32P-PAI-1 was stored in aliquots at  20 jC. The ability of
the prepared 32P-PAI-1 to form a covalently linked complex
with uPA was measured by reacting 0.5-ng 32P-PAI-1
(approximately 10 14 mol) with 3-Ag low molecular
weight uPA (uPA N-terminally truncated at Lys136) for 15
min at 37 jC. As judged by SDS-PAGE and densitometry
by the use of a PhosphorImager (Molecular Dynamics,
Amersham-Pharmacia Biotek, Sweden), about 50% was
able to form a complex with uPA, the rest being inert to
uPA and presumably latent.
2.4. Antibodies
The monoclonal anti-vitronectin antibody 8E6 [29] was a
gift from Dr. D.F. Mosher, Madison, WI, USA. The mono-
clonal anti-vitronectin antibody BV2 was purchased from
Chemicon International (Temecula, CA, USA; code
MAB1945). The monoclonal anti-vitronectin antibody
16A7 [30] was a gift from Dr. K.T. Preissner, Giessen,
Germany. A monoclonal anti-CD34 antibody (clone QB-
End10) was purchased from Immunotech (Immunotech,
France). A monoclonal anti-Aspergillus niger glucose oxi-
dase antibody, of the IgG1 subtype, was purchased from
DAKO (Glostrup, Denmark; code X0931). Monoclonal
anti-human uPA antibody from hybridoma clone 2 has been
described previously [31]. The monoclonal anti-human PAI-
1 antibody MA33B8 [32] was a gift from Dr. P.J. Declerck,
Leuven, Belgium. A monoclonal antibody against human
serum albumin was a gift from H. Palsdottir, Department of
Medical Biochemistry, Aarhus University, Denmark.
2.5. Immunohistochemistry
Frozen sections were stained with the monoclonal anti-
vitronectin antibodies 8E6 and BV2 in concentrations of 0.5
and 2.0 Ag/ml, respectively. Sites of antigen–antibody
reaction were visualised with the Envision +k system
(DAKO; code K4003).Formalin-fixed, paraffin-embedded sections were depar-
affinised, rehydrated, boiled in a microwave oven in buffer
twice for 5 min, allowed to cool at room temperature for 20
min, and then incubated in 2% H2O2 in 99% ethanol at room
temperature for 20 min to block endogenous peroxidase.
One of two buffers was used in the microwave oven treat-
ment, depending on the primary antibody. One buffer was
10 mM Tris, pH 9.0, 0.5 M EGTA buffer, used in combi-
nation with 2 Ag/ml monoclonal anti-vitronectin antibody
BV2, or anti-CD34 diluted 1:1000. The other buffer was a
10 mM sodium citrate, pH 6.0, used in combination with 0.5
Ag/ml monoclonal anti-vitronectin antibody 8E6. The pri-
mary antibodies were visualised with the Envision visual-
isation system and the chromogen 3-amino-9-ethylcarbazole
(Sigma-Aldrich; code A-5754), followed by counterstaining
with Mayer’s haematoxylin and mounting in Glycergel
(DAKO; code C0563). The negative control antibodies were
used in a concentration of 5 Ag/ml. Triton X-100, in a
concentration of 0.5%, was added to the buffer used for
intervening washes after the primary antibody had been
applied, to avoid unspecific adhesion of the antibodies to the
tissues.
2.6. Solid phase radioligand assay for vitronectin
For analysis of the vitronectin content of samples of
tissue extracts and plasma, the wells of HighBind microtiter
plates (Corning, NY, USA) were coated with varying
dilutions of the samples. Series of twofold dilutions of the
samples were performed directly in the wells, spanning the
range 0.6 to 0.075 Ag protein per well, in a total volume of
100-Al 10 mM sodium phosphate, pH 7.4, 0.14 M NaCl, 10
mM EDTA, 2 Ag/ml Trasylol per well. In addition to the
sample dilution series, each plate also contained, in dupli-
cate, a twofold dilution series of purified multimeric vitro-
nectin, from 50 to 0.012 ng vitronectin per well, to be used
as a standard curve, as well as a dilution series of a reference
sample of human plasma. In addition, four wells per plate
were coated with buffer only, allowing determination of
background binding. The plates were then incubated at 37
jC for 2 h. After this incubation, the samples were carefully
removed and the plates blocked with 5% BSA (in the same
buffer as used for the coating) for 1 h at 37 jC. This was
followed by washing three times with 10 mM sodium
phosphate, 0.14 M NaCl, 0.05% Tween-20. Each well then
received 100-Al 0.84 nM 32P-PAI-1, in the same buffer as
used for the coating. The plates were then incubated for 16 h
on ice. After the incubation, the supernatants were removed
and the wells washed thoroughly with buffer. The radio-
activity in the supernatants and the radioactivity bound to
the wells were determined by liquid scintillation counting
with a Packard TopCount NXTk microplate scintillation
counter. Generally, the ratios between the radioactivity in
the supernatants and the radioactivity bound to the wells
were used for the further calculations, after a correction for
the background binding in wells coated with buffer only.
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vitronectin were determined as previously described [33].
2.7. Ligand blot analysis
Samples of human plasma or tissue extracts were
resolved by SDS-PAGE in 11% gels. In some cases, the
samples were subjected to mild reduction (20 mM dithio-
threitol, 1 h, 37 jC) before electrophoresis. After electro-
phoresis, the proteins were transferred electrophoretically
from the gels to polyvinylideneflouride (PVDF) filters
(Immobilon-P, Millipore, Glostrup, Denmark) in a buffer
of 25 mM Tris, 192 mM glycine, pH 8.0, at 100 V for 1
h, using a Mini Trans Blot Electrophoretic Transfer Cell
from Bio-Rad. The filters were blocked with a buffer of 10
mM NaH2PO4, pH 7.4, 0.14 M NaCl with 5% skim milk
and 0.05% Tween-20 for 16 h at 4 jC, followed by
incubation with 32P-PAI-1 at a concentration of 0.3 nM
at room temperature over night in 10 mM Na2HPO4, 20
mM HEPES, pH 7.4, 140 mM NaCl, 0.05% Tween-20
(PBS-T), supplemented with 5% skim milk. After incuba-
tion, the membranes were washed three times for 15 min
with PBS-T. Bound ligands were visualized by a Phos-
phorImager (Molecular Dynamics, Amersham-Pharmacia
Biotek).
2.8. ELISA measurement of uPA and PAI-1
The levels of uPA and PAI-1 in tissue extracts were
determined by sandwich ELISAs, as described before [24].
2.9. Hemoglobin in tissue and cell extracts
The absorption spectra of suitably diluted extracts of
tissue or red blood cells were measured in the range 300 to
800 nm by the use of a Power Wawex ELISA reader
(Biotek Instruments). The hemoglobin content of the
extracts was calculated by comparing the heights of the
absorption spectra at 400 nm to the heights of the peaks
from known concentrations of hemoglobin (type X, Sigma-
Aldrich).
2.10. RT-PCR analysis of the occurrence of vitronectin
mRNA
Total RNAwas isolated from tissue lumps or cultured cells
by the guanidinium thiocyanate–phenol–chloroform (GTC)
extraction method [34]. The reverse transcriptase reaction
was performed with the First Strand cDNA Synthesis Kit
from Pharmacia-Biotech, using 1–2 Ag RNA. One-microliter
cDNA solution was used for each PCR reaction. The primers
for vitronectin were 5V-ATGGGTTGCTCTGGCTGAC-3Vand
5V-CTGCTGGGGGCTGAGGTCT-3V, corresponding to
nucleotides 103–121 and 497–515, respectively, of the
vitronectin sequence [35]. These primers are expected to give
a PCR product of 413 bp. Amplification of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA was performed
in parallel in order to evaluate the efficiency of the RNA
extraction procedure and cDNA synthesis. The two GAPDH
primers were 5V-GGTCGGAGTCAACGGATTT-3V and 5V-
CCAGCATCGCCCCACTTGA-3V [36]. They were expected
to give a PCR product of 258 bp. All primers were purchased
from DNA Technology (Aarhus, Denmark). The PCR reac-
tions were performed by standard procedures with 30 cycles.
The PCR products were electrophoresed in a 1.5% agarose
gel and visualised by ethidium bromide staining.
2.11. Statistical analysis
Correlations between sets of data were tested by the
Spearman rank correlation test, by the use of the Analyse-it
software www.analyse-it.com). Nonlinear regression analy-
sis, by the method of least squares, was performed by the
SigmaPlot program (Jandel Scientific Software, San Rafael,
CA, USA).3. Results
3.1. Immunohistochemical analysis of human breast
carcinomas and normal breast tissue for vitronectin
To study the localisation of vitronectin in invasive ductal
breast carcinomas and normal breast tissue, we immunohis-
tochemically analysed frozen sections and formalin-fixed,
paraffin-embedded sections with two different monoclonal
antibodies. Using a series of parallel sections of each of six
carcinomas, identical staining patterns were obtained with
both antibodies and with both types of sections.
Vitronectin was often abundantly accumulated in the
connective tissue around ducts with cancer cells and islands
of cancer cells (Fig. 1A and E). As judged from parallel
stainings with monoclonal anti-CD34 antibody, the vitro-
nectin immunoreactivity surrounding cancer cells was
localized in the vicinity of, although not in close association
with, capillaries and small vessels (Fig. 1B and F). Fur-
thermore, in microvessels, the vitronectin immunoreactivity
was found in the subendothelial regions in close proximity
to the endothelial cells or in relation to the lamina elastica
and the surrounding tunica adventitia (Fig. 1A and B). On
the other hand, large areas with many cancer cells and
many microvessels contained no or little vitronectin (Fig.
1C and D). Also normal breast tissue displayed a hetero-
geneous distribution of vitronectin immunoreactivity. Vitro-
nectin immunoreactivity had a homogeneous periductal
occurrence (Fig. 1H), but the staining pattern was clearly
different from that seen around the malignant epithelial
cells in the carcinomas, the local accumulation in the
normal tissue being much less distinct and intense. In
addition, the normal tissue showed occasional staining of
the subendothelial regions of some of the small vessels (not
shown).
Fig. 1. Immunohistochemical analysis of the occurrence of vitronectin in human breast tissue. (A and B) Parallel sections of a human invasive ductal breast
carcinoma were analysed with monoclonal anti-vitronectin antibody 8E6 (A) and monoclonal anti-CD34 for detection of endothelial cells (B). Vitronectin is
localised in the subendothelial region of small vessels (white arrows) and in extracellular matrix-structures, often periductally, in the vicinity of larger vessels
(black arrows). (C and D) Another area of the same tumour as in A and B was stained with monoclonal anti-vitronectin antibody BV2 (C) or monoclonal anti-
CD34 (D). In spite of many small vessels, this area contains very little vitronectin. (E–G) Parallel sections of a human invasive ductal breast carcinoma were
analysed with monoclonal anti-vitronectin antibody BV2 (E) and monoclonal anti-CD34 (F), and a monoclonal anti-Aspergillus niger glucose oxidase
antibody, as a negative control (G). There is a prominent occurrence of vitronectin in an extracellular matrix structure surrounding a duct filled with cancer
cells. The same area contains many small vessels. (H) A section of normal breast glandular tissue was analysed with monoclonal anti-vitronectin antibody 8E6.
Periductal staining was observed. The size bars indicate 100 Am.
M. Aaboe et al. / Biochimica et Biophysica Acta 1638 (2003) 72–8276
Fig. 3. Effect of monoclonal antibodies on the binding of 32P-PAI-1 to
human breast carcinoma extract protein immobilised on microtiter plates.
The wells of a microtiter plate were coated with extract of a human invasive
ductal breast carcinoma in an amount corresponding to 0.3 Ag total protein.
One-hundred-microliter portions of 32P-PAI-1 (0.84 nM) were preincubated
for 30 min at 0 jC without antibody, with 50 Ag/ml monoclonal anti-PAI-1
antibody MA33B8, or with 50 Ag/ml monoclonal anti-human serum
albumin (anti-HAS) antibody before being added to the coated wells.
Likewise, the coated wells were preincubated for 30 min without antibody
or with 50 Ag/ml monoclonal anti-vitronectin (anti-VN) antibody 16A7 or
with 50 Ag/ml monoclonal anti-uPA antibody before addition of 32P-PAI-1.
The amount of bound 32P-PAI-1 at each incubation condition was expressed
as a fraction of that measured in the absence of antibody. Means and ranges
of double determinations are indicated.
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specificity) always gave completely blank sections (Fig.
1G).
3.2. Characterisation of a solid phase radioligand assay for
vitronectin
The strategy of the developed solid phase radioligand
vitronectin assay consists in immobilisation of vitronectin in
wells of microtiter plates and estimation of the amount of
immobilised vitronectin from its capacity for binding radio-
labeled PAI-1. A recombinant PAI-1, with an HMK phos-
phorylation site added to the amino terminus of PAI-1, was
constructed, expressed in E. coli, purified, and labelled with
the use of HMK and g-32P-ATP.
For a standard curve, we used purified multimeric vitro-
nectin. The binding of 32P-PAI-1 to purified, multimeric
vitronectin was of high affinity (see below) and could be
inhibited by some monoclonal anti-PAI-1 antibodies [33]
and by the monoclonal anti-vitronectin-antibody 16A7 (data
not shown). With the 32P-PAI-1 concentration and the
volume used in the assays (0.84 nM and 100 Al, respec-
tively, corresponding to a total amount of 0.084 pmol PAI-1
per well), the bound to free ratio (B/F) for 32P-PAI-1 was
linearly related to the amount of vitronectin in the coating
solutions up to a B/F value of about 0.25 and about 5 ng or
0.06 pmol vitronectin (Fig. 2). The standard deviation for
the slope of the linear part of standard curves performed
with different microtiter plates on the same day was 5.9%
(n = 6). The standard deviation for the slope of standard
curves performed at the different days was 9.5% (n = 9).
To estimate the amount of vitronectin in samples of
human plasma and extracts of human breast tissues, sampleFig. 2. Standard curve for the solid phase radioligand vitronectin assay. The
indicated amounts of purified multimeric vitronectin was coated on the
wells of microtiter plates. The wells were then incubated with 0.84 nM 32P-
PAI-1. The amounts of bound and free 32P-PAI-1 were determined by
scintillation counting and their ratio (B/F) calculated. Means and ranges of
double determinations are indicated. The line indicated corresponds to the
best fit obtained by a linear regression analysis of the data pairs with a
vitronectin amount less than or equal to 5 ng.volumes corresponding to several amounts of total protein,
up to 1 Ag, diluted to a total volume of 100 Al, were coated
in the wells of microtiter plates. For the coating, the samples
were incubated for 2 h at 37 jC. The choice of this coating
condition was based on the observation that when coating
with plasma, the amount of 32P-PAI-1 bound to the plates
was about threefold higher after coating at 37 jC as
compared to coating at 0 jC, while there was no difference
between coating at 0 and 37 jC when coating with purified
multimeric vitronectin or tissue extract (data not shown). As
vitronectin undergoes the structural transition leading to
multimerisation by adsorption to surfaces [37], this obser-
vation is in agreement with coating at 37 jC ensuring full
conversion to the multimeric state during coating. The
binding of 32P-PAI-1 to the coated microtiter wells could
be blocked by a monoclonal anti-vitronectin antibody and
by a monoclonal anti-PAI-1 antibody, while there was no
effect of a monoclonal anti-uPA antibody and a monoclonal
anti-human serum albumin antibody (Fig. 3). The Kd values
for binding of PAI-1 to wells coated with purified multi-
meric vitronectin, tumour extract, or blood plasma were
101F 21 pM (n = 3), 88F 18 pM (n = 3), and 79F 37 pM
(n = 3), respectively, in good agreement with the value
previously reported for purified multimeric vitronectin
[33]. The curves relating B/F values to amounts of tissue
and plasma protein were linear up to a B/F value of about
Fig. 5. Ligand blot analysis of binding of 32P-PAI-1 to purified vitronectin
or samples of breast carcinoma extracts. Purified vitronectin (25 ng) or
tumour extracts (15 Ag of total protein) were subjected to SDS-PAGE in
gels with 11% polyacrylamide under nonreducing (A) or mildly reducing
(B) conditions. The proteins were transferred electrophoretically from the
gels to PVDF filters, which were then incubated with 0.30 nM 32P-PAI-1.
Bound radioactivity was visualised by a PhosphorImager. The migration of
Mr markers are indicated to the left. The migrations of the three vitronectin
variants multimeric vitronectin, Mr 75,000 monomeric vitronectin, and the
Mr 65,000 degradation product (VNm, VN75, VN65, respectively) are
indicated to the right.
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control for the recovery of vitronectin from tissue extracts,
extracts were supplemented with different amounts of puri-
fied vitronectin (Fig. 4). Measuring the slopes of the lines
relating B/F and amounts of protein in the coating solutions
in the presence of various amounts of added purified
vitronectin, the recovery of the added vitronectin was
99.4F 6.6% (n = 3). Thus, the recovery of the added inter-
nal standard was not significantly different from 100%.
The specificity of the assay was also controlled by ligand
blot analysis. After electrophoresis under nonreducing con-
ditions, extracts of both carcinomas (Fig. 5) and normal
tissue (not shown) displayed three PAI-1 binding bands, all
co-migrating with bands in purified multimeric vitronectin.
These include a band of multimeric vitronectin, a band of
monomeric Mr 75,000 monomeric vitronectin, and the Mr
65,000 degradation product. The ligand blots had no signals
in positions corresponding to Mr below 65,000. After
electrophoresis under mildly reducing conditions, all PAI-
1 binding activity migrated as two bands with Mr 75,000 or
Mr 65,000, showing that the multimeric bands are held
together by disulfide bonds, while the mild conditions used
during reduction do not lead to reduction of the disulfide
bonds in the PAI-1 binding somatomedin B domain, pre-
sumably due to its compact structure.
The amounts of vitronectin in a sample (in nanograms of
vitronectin per nicrogram of total protein) were calculated as
the slope of the line relating B/F and micrograms of total
protein in the sample divided by the slope of the line relating
B/F and nanograms of purified vitronectin in the standard.Fig. 4. Recovery of purified vitronectin added to tumour extracts. The
indicated amounts of purified multimeric vitronectin was mixed with
portions of extracts of a human ductal breast carcinoma corresponding to
the indicated amounts of total protein. The mixtures were coated in the
wells of microtiter plates. The wells were then incubated with 0.84 nM 32P-
PAI-1. The amounts of bound and free 32P-PAI-1 were determined by
scintillation counting and their ratio (B/F) calculated. The parameters of the
lines drawn were determined by linear regression analysis. Relative to the
slope of the line without addition of purified vitronectin, the slopes of the
other lines were: + 0.2 ng vitronectin, 1.04; + 0.5 ng vitronectin, 0.91; + 1
ng vitronectin, 1.01. The results of a larger number of recovery experiments
are summarised in the text.The detection limit was estimated to be 0.1 ng vitronectin/
Ag total protein, from the minimal slopes of the lines
significantly different from 0. The standard deviation for
the signal obtained from the reference human plasma sample
in assays on different days was 28.3% (n = 11).
The details of the routine procedure for the assay is given
in Materials and methods.
3.3. The levels of vitronectin in extracts of human breast
tissue
With the developed assay, we measured the level of
vitronectin in extracts of 70 human breast carcinomas, in
extracts of 19 normal human breast tissue samples, and in 11
human plasma samples (Table 1). The vitronectin concen-
trations in human plasma samples were estimated to have a
mean value of 4.5 Ag vitronectin/mg total protein or 316 Ag
vitronectin/ml, in excellent agreement with previous esti-Table 1
Levels of vitronectin in human plasma and extracts of human ductal breast











Carcinomas 0.43F 0.32a 5.69F 2.04 2.38F 1.92
Normal breast 1.96F 1.24 2.83F 0.76 5.92F 3.86
Plasma 4.51F 0.88 65.0F 2.7 316F 31
The 70 samples of malignant carcinomas had a vitronectin content ranging
from < 0.1 to 1.9 ng vitronectin/Ag total protein. The 19 samples of control
breast tissue had a vitronectin content ranging from < 0.1 to 2.7 ng
vitronectin/Ag total protein. The 11 samples of control human plasma had a
vitronectin content ranging from 2.6 to 5.8 ng vitronectin/Ag total protein.
a Mean and standard deviations are indicated.
Fig. 6. RT-PCR analysis of vitronectin mRNA in human breast carcinomas.
RNA was extracted from human breast carcinomas, normal human breast
tissue, or HepG2 cells, and used as a template for reverse transcription. The
resulting cDNA was amplified by PCR, with GAPDH or vitronectin
primers, as indicated. The resulting PCR products were electrophoresed in
1.5% agarose gels. Size markers (a mixture of pBR328 plasmid digested
with BglI and pBR328 digested with HinfI) are shown to the left (M). Lanes
1–4 show the result of analysis of RNA from four samples of normal breast
tissue. Lanes 5 and 7–9 show the result of analysis of RNA from four
ductal carcinomas. Lane 6 shows the result of analysis of RNA from HepG2
cells. PCR amplification in the absence of cDNA gave no signal.
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[38–40]. Extracts of both carcinomas and normal breast
tissue had vitronectin levels around 1 Ag vitronectin/mg
total protein or around 4 Ag vitronectin/ml, with consider-
able variation between different extracts. With an estimated
dilution of a factor of around 10 during tissue extraction, the
average vitronectin content of the intact tissues could be
estimated to about 40 Ag/ml or about 10-fold lower than the
plasma level.
The similarity of the vitronectin levels in normal breast
tissue and breast carcinomas was confirmed on a semi-
quantitative basis by ligand blot analysis with 32P-PAI-1
(data not shown). The efficiency of the tissue extraction
procedure was evaluated by re-extraction of the pellets from
the first extraction with SDS-PAGE sample buffer, contain-
ing 3% SDS, followed by SDS-PAGE under mildly reduc-
ing conditions and ligand blotting analysis. By densitometric
scannings of autoradiograms, we found that 78.6F 2.5%
(n = 4) of the total amount of vitronectin was recovered by
the extraction.
In order to quantitate the blood contamination in the
tissue extracts, we measured their hemoglobin concentra-
tion. On the basis of the hemoglobin content of the extracts,
we estimated that the vitronectin resulting from blood
contamination could maximally account for 0.01 Ag vitro-
nectin/mg total protein, only about 1% of the vitronectin
content was actually found. Moreover, we found no corre-
lation between this parameter and the vitronectin concen-
tration (data not shown). Therefore, the vitronectin content
of the extracts was not caused by blood contamination.
The uPA content of the carcinomas varied from 0.1 to
78.5 ng/mg total protein, with a mean value of 3.3 ng/mg
total protein. For PAI-1, the limits were 0.7 and 31.0 ng/mg
total protein, with a mean value of 5.1 ng/mg total protein.
The vitronectin concentration of the tumour extracts was not
related to the uPA or the PAI-1 concentration (data not
shown). Importantly, the uPA and PAI-1 concentrations
were 10–1000-fold lower than the vitronectin concentra-
tions.
3.4. Analysis of the occurrence of vitronectin mRNA
RNAwas extracted from 17 breast carcinomas, including
15 ductal carcinomas and 2 tubular carcinomas, from 3
lymph node metastases, from 10 samples of normal breast
tissue, and from HepG2 human hepatoma cells. The
extracted RNA was analysed for the presence of vitronectin
mRNA by RT-PCR analysis. The synthesised cDNA was
then amplified by the use of two vitronectin primers,
expected to yield a product of 413 bp, and, as a control,
two GAPDH primers, expected to yield a product of 258 bp.
Amplification of cDNA from HepG2 cells gave a
vitronectin PCR product of about 0.4 kbp, in agreement
with the expected size of 413 bp. In contrast, no PCR
product was obtained with RNA from any of the breast
carcinomas, lymph node metastases, or normal breast tissuesamples (Fig. 6). This was not caused by degradation of the
RNA, as the expected signal was obtained with the
GAPDH primers (Fig. 6). The absence of a vitronectin
mRNA signal persisted when 60 cycles of amplification
were employed instead of the routinely used 30 cycles (data
not shown). Thus, vitronectin mRNA could not be detected
in neither normal human breast tissue or human breast
carcinomas.
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In this report, we describe an immunohistochemical
analysis of the occurrence of vitronectin in human breast
carcinomas and normal human breast tissue. For the stain-
ings, we used two monoclonal anti-vitronectin antibodies
directed against different epitopes. The two antibodies
showed identical staining patterns on frozen and formalin-
fixed, paraffin-embedded sections and stained well even
with very low antibody concentrations. The subtype-
matched negative control monoclonal antibody of irrelevant
specificity gave no staining. The use of two monoclonal
antibodies against the antigen of interest and the use of a
monoclonal antibody of irrelevant specificity are necessary
to assure the specificity of the stainings and thus to obtain
conclusive results. When using polyclonal antibodies, the
immunohistochemical analysis must be supported by
absorption controls and immunoblotting analysis [5,41].
Others, using less extensive controls, previously reported
the occurrence of vitronectin in breast carcinomas [42–44].
Vitronectin was reported to be present in the peritumoural
stroma and in blood vessel walls and fibroblasts [42] or as
fibrillar deposits in connective tissue matrix as diffuse
deposits around tumour cells [43,44], localisations over-
lapping with, but not identical to, our vitronectin local-
isation. Our immunohistochemical analysis of ductal breast
carcinomas showed a particularly prominent accumulation
of vitronectin in ECM structures surrounding islands of
cancer cells and ducts filled with cancer cells. Vitronectin
was also present as extracellular deposits in close relation to
vessels, in the subendothelial regions. However, large areas
of ductal carcinomas without vitronectin was also found, in
spite of the parallel CD34 analysis revealing many micro-
vessels in these areas. In normal breast tissue, vitronectin
was seen in relation to mammary ducts and occasionally in
relation to small vessels. Thus, the differences in tissue
architecture of normal tissue and carcinomas are correlated
with distinctly different vitronectin distribution patterns.
We also describe the development of a solid phase
radioligand assay for vitronectin in tissue extracts. On the
basis of a number of control experiments, we concluded that
the assay was specific, that it was reproducible, that it was
sensitive enough in the present context, and that it displayed
full recovery of internal standards. In particular, there was
no detectable binding of 32P-PAI-1 to proteins other than
vitronectin, also not uPA (Mr 58,000) and a1-acid glyco-
protein (Mr 25,000), which was recently reported to bind
PAI-1 with an affinity about 10-fold lower than that for
vitronectin [45]. The vitronectin concentrations found in
human plasma were in excellent agreement with those
previously found by ELISA and other immunological meth-
ods [38–40]. By the use of the assay, we measured the
vitronectin concentrations in extracts of human breast car-
cinomas and of normal breast tissue. In spite of the clearly
different immunohistochemical staining patterns, the levels
of vitronectin in extracts of the carcinomas were notsignificantly different from those in extracts of normal
breast tissue.
We were unable to detect vitronectin mRNA in breast
carcinomas and in normal breast tissue by the use of RT-
PCR. Since there is no general correlation between the
cellular level of a protein and that of its mRNA, our result
does not necessarily exclude the presence of vitronectin-
producing cells in the carcinomas. However, the lack of
detectable vitronectin mRNA is in stark contrast to the
levels of PAI-1 mRNA in breast carcinomas, which are
readily detectable by RT-PCR [46], in spite of the fact that
the level of PAI-1 protein was now found to be 10–1000-
fold lower than that of vitronectin protein. It therefore seems
that locally produced vitronectin can at most constitute a
minor fraction of the total amount present in the tissue. It
also seemed highly unlikely that the vitronectin content of
the tissue extracts is derived from blood contamination, a
conclusion which is also in agreement with the results of the
immunohistochemical analysis. Taken together, our obser-
vations point to the conclusion that the vitronectin in normal
and malignant breast tissue is derived from the plasma
vitronectin pool by extravasation. A variety of mechanisms
for trans-endothelial transport of vitronectin have been
discussed (for a review, see Ref. [3]). Following penetration
into the tissue, it accumulates in specific areas in patterns
distinctly different in carcinomas and in normal tissue,
perhaps by binding to other ECM constituents (see Intro-
duction). An extravasation mechanism is in agreement with
the observation that the vitronectin concentrations of tissues
were found to be around 10-fold lower than that of plasma.
In view of the present results, the bulk of vitronectin in other
tumours, in which vitronectin was previously reported to be
present [44,47–53], is also likely to be derived by extrav-
asation.
Being a ligand for uPAR and several integrins, vitronec-
tin may play an important role in tumours by providing
traction and direction to migrating tumour cells during
invasion and/or migrating endothelial cells during angio-
genesis. The observed immunohistochemical localisation of
vitronectin is not in contradiction to a hypothesis of such a
role, which must, however, be substantiated by future
studies of the relative localisation of vitronectin, uPAR,
and integrins. The observations that PAI-1 compete with
uPAR and integrins for binding to vitronectin (for reviews,
see Refs. [5,6]) suggest that PAI-1 may be a regulator of
vitronectin-dependent cell adhesion and migration. How-
ever, we report here that the vitronectin levels in the tissue
extracts are 10–1000-fold higher than the PAI-1 levels. This
observation is in apparent contradiction to the hypothesis of
a role of PAI-1 in regulating the adhesive functions of
vitronectin in breast tumours, as this regulatory function is
based on formation of complexes between PAI-1 and
vitronectin of 1:1 stoichiometry. This conclusion is in
agreement with the conclusion of recent work with animal
and cell culture model systems of tumour invasion and
angiogenesis, indicating that the role of PAI-1 in these
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than its ability to bind to vitronectin [54–56]. This sugges-
tion is in good agreement with the apparent lack of coloc-
alisation of PAI-1 and vitronectin when comparing the
present immunohistochemical analysis of vitronectin local-
isation and previous immunohistochemical localisations of
PAI-1 (for a review, see Ref. [5]). Nevertheless, it is still
possible that in the microenvironment in tumours, vitronec-
tin may be present in the vicinity of PAI-1 producing cells in
concentrations which may both be active in supporting cell
migration and which are similar to those of PAI-1. An
answer to these questions must await an accurate study of
the relative localisation of vitronectin and PAI-1 in tumours.Acknowledgements
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